BCPC on Nasdaq
BALCHEM CORP
American chemicals and allied products company based in Baltimore2
In its 2026 annual report the company says: “We develop, manufacture, distribute and market specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, plant nutrition, sterilization, fumigation, and industrial markets. Our three reportable segments are strategic businesses that offer products and services to different markets: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. We sell our products through our own sales force, independent distributors and sales agents.”5 Its shares trade on Nasdaq under the symbol BCPC.2
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with Ingevity Corp, Ecovyst Inc. or Perimeter Solutions, Inc., or pick any stock.
- TickerBCPC on Nasdaq2
- IndustryChemicals & Allied Products2
- HeadquartersBaltimore, United States2
- Incorporated inMD3
- Business address5 Paragon Drive, Montvale, Nj 076453
- Filer categoryLarge accelerated filer3
- Legal formStock Corporation2
- LEI549300VR70OPMHUI35572
- StatusActive2
- LEI statusLapsed (not renewed)2
- Registered address7 ST. PAUL STREET, 21202 Baltimore, United States2
- Registered withBusiness Services (Maryland Department of Assessments and Taxation), D000518882
See how the biggest companies compare on our leaderboards
Balchem Corporation (“Balchem,” the “Company,” “we” or “us”), was incorporated in the State of Maryland in 1967. We develop, manufacture, distribute and market specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, plant nutrition, sterilization, fumigation, and industrial markets. Our three reportable segments are strategic businesses that offer products and services to different markets: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. Sales and production of products outside of our reportable segments and other minor business activities are included in "Other and Unallocated".5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Product Sales brought in 100% of the revenue BALCHEM CORP broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Product Sales | $920.0M | $951.9M | $1.0B |
| Royalty | $2.5M | $1.7M | $1.9M |
Business segments
Human Nutrition and Health brought in 64% of the revenue BALCHEM CORP broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2023 | 2024 | 2025 |
|---|---|---|---|
| Human Nutrition and Health | $550.8M | $600.3M | $659.4M |
| Animal Nutrition and Health | $238.3M | $214.7M | $230.9M |
| Specialty Products | $126.0M | $132.7M | $141.0M |
Regions
United States brought in 73% of the revenue BALCHEM CORP broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $689.6M | $723.3M | $759.4M |
| Outside the United States | $232.8M | $230.4M | $277.7M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue64¢$666.5M
- Research and development2¢$18.5M
- Other costs15¢$153.1M
- Income tax4¢$44.2M
- Profit15¢$154.8M
Out of $1.0B in revenue.6
Where each dollar of operating cash went, fiscal 2025
- Dividends paid13¢$28.3M
- Share buybacks50¢$107.6M
- Kept or used elsewhere37¢$80.6M
Out of $216.6M of cash from operations.6
Financial statements
Every line of the income statement as filed: the last 3 fiscal years (annual) or 8 quarters (quarterly), latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net sales | $1.0B | $953.7M | $922.4M |
| Cost of sales | $666.5M | $617.5M | $620.4M |
| Gross margin | $370.6M | $336.2M | $302.1M |
| Selling expenses | $75.4M | $68.9M | $74.4M |
| Research and development expenses | $18.5M | $16.8M | $15.0M |
| General and administrative expenses | $67.4M | $67.6M | $53.4M |
| Total operating expenses | $161.3M | $153.3M | $142.9M |
| Earnings from operations | $209.3M | $182.9M | $159.2M |
| Interest expense, net | $10.2M | $16.5M | $22.6M |
| Other expense (income), net | $77.0K | -$72.0K | -$681.0K |
| Total other expenses | $10.3M | $16.5M | $21.9M |
| Earnings before income tax expense | $199.0M | $166.5M | $137.3M |
| Income tax expense | $44.2M | $38.0M | $28.7M |
| Net earnings | $154.8M | $128.5M | $108.5M |
| Net earnings per share - basic (in dollars per share) | $4.80 | $3.97 | $3.38 |
| Diluted net earnings per common share (in dollars per share) | $4.75 | $3.93 | $3.35 |
| Period ending | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|
| Net sales | $263.6M | $267.6M | $255.5M | $250.5M | $240.0M | $239.9M | $234.1M | $239.7M |
| Gross margin | $93.9M | $95.5M | $93.1M | $88.2M | $86.3M | $85.4M | $83.0M | $81.5M |
| Earnings before income tax expense | $50.0M | $52.0M | $49.0M | $47.9M | $44.5M | $43.9M | $41.2M | $36.9M |
| Net earnings | $39.2M | $40.3M | $38.3M | $37.1M | $33.6M | $33.8M | $32.1M | $29.0M |
| Net earnings per share - basic (in dollars per share) | $1.23 | $1.25 | $1.18 | $1.14 | $1.05 | $1.05 | $0.99 | $0.90 |
| Diluted net earnings per common share (in dollars per share) | $1.21 | $1.24 | $1.17 | $1.13 | $1.03 | $1.03 | $0.98 | $0.89 |
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $74.6M | $49.5M | ||
| Accounts receivable, net of allowance for credit losses of $862 and $909 at December 31, 2025 and 2024, respectively | $143.6M | $119.7M | $125.3M | |
| Inventories, net | $131.4M | $130.8M | ||
| Prepaid expenses | $9.8M | $8.1M | ||
| Other current assets | $6.2M | $5.7M | ||
| Total current assets | $365.6M | $313.8M | ||
| Property, plant and equipment, net | $306.6M | $282.2M | ||
| Goodwill | $816.4M | $780.0M | $778.9M | |
| Customer relationships and lists | $133.0M | $132.5M | ||
| Other intangible assets with finite lives, net | $30.3M | $32.6M | ||
| Right of use assets - operating leases | $14.7M | $15.3M | ||
| Right of use assets - finance lease | $1.5M | $1.7M | ||
| Other non-current assets | $18.1M | $17.3M | ||
| Total assets | $1.7B | $1.6B | ||
| Trade accounts payable | $60.4M | $54.7M | ||
| Accrued expenses | $49.3M | $43.8M | ||
| Accrued compensation and other benefits | $27.9M | $22.9M | ||
| Dividends payable | $31.0M | $28.5M | $25.7M | |
| Income tax payable | $3.9M | $4.5M | ||
| Operating lease liabilities - current | $3.6M | $3.1M | ||
| Finance lease liabilities - current | $205.0K | $194.0K | ||
| Total current liabilities | $176.4M | $157.7M | ||
| Revolving loan | $164.0M | $190.0M | ||
| Deferred income taxes | $54.1M | $43.7M | ||
| Operating lease liabilities - non-current | $11.3M | $13.0M | ||
| Finance lease liabilities - non-current | $1.5M | $1.7M | ||
| Other long-term obligations | $21.4M | $19.3M | ||
| Total liabilities | $428.8M | $425.5M | ||
| Preferred stock, $25 par value. Authorized 2,000,000 shares; none issued and outstanding | $0 | $0 | ||
| Common stock, $.0667 par value. Authorized 120,000,000 shares; 32,058,121 shares issued and outstanding at December 31, 2025 and 32,527,244 shares issued and outstanding at December 31, 2024, respectively | $2.1M | $2.2M | ||
| Additional paid-in capital | $92.3M | $174.0M | ||
| Retained earnings | $1.1B | $997.5M | ||
| Accumulated other comprehensive income (loss) | $41.5M | -$23.7M | ||
| Total stockholders equity | $1.3B | $1.1B | $1.1B | $938.3M |
| Total liabilities and stockholders equity | $1.7B | $1.6B | ||
| Accounts receivable, allowance for doubtful accounts | $862.0K | $909.0K | ||
| Preferred stock, par value (in dollars per share) | $25.00 | $25.00 | ||
| Preferred stock, shares authorized (in shares) | 2.0M shares | 2.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.07 | $0.07 | ||
| Common stock, shares authorized (in shares) | 120.0M shares | 120.0M shares | ||
| Common stock, shares issued (in shares) | 32.1M shares | 32.5M shares | ||
| Common stock, shares outstanding (in shares) | 32.1M shares | 32.5M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $74.6M | $49.5M | ||
| Accounts receivable, net of allowance for credit losses of $862 and $909 at December 31, 2025 and 2024, respectively | $143.6M | $119.7M | $125.3M | |
| Inventories, net | $131.4M | $130.8M | ||
| Prepaid expenses | $9.8M | $8.1M | ||
| Other current assets | $6.2M | $5.7M | ||
| Total current assets | $365.6M | $313.8M | ||
| Property, plant and equipment, net | $306.6M | $282.2M | ||
| Goodwill | $816.4M | $780.0M | $778.9M | |
| Customer relationships and lists | $133.0M | $132.5M | ||
| Other intangible assets with finite lives, net | $30.3M | $32.6M | ||
| Right of use assets - operating leases | $14.7M | $15.3M | ||
| Right of use assets - finance lease | $1.5M | $1.7M | ||
| Other non-current assets | $18.1M | $17.3M | ||
| Total assets | $1.7B | $1.6B | ||
| Trade accounts payable | $60.4M | $54.7M | ||
| Accrued expenses | $49.3M | $43.8M | ||
| Accrued compensation and other benefits | $27.9M | $22.9M | ||
| Dividends payable | $31.0M | $28.5M | $25.7M | |
| Income tax payable | $3.9M | $4.5M | ||
| Operating lease liabilities - current | $3.6M | $3.1M | ||
| Finance lease liabilities - current | $205.0K | $194.0K | ||
| Total current liabilities | $176.4M | $157.7M | ||
| Revolving loan | $164.0M | $190.0M | ||
| Deferred income taxes | $54.1M | $43.7M | ||
| Operating lease liabilities - non-current | $11.3M | $13.0M | ||
| Finance lease liabilities - non-current | $1.5M | $1.7M | ||
| Other long-term obligations | $21.4M | $19.3M | ||
| Total liabilities | $428.8M | $425.5M | ||
| Preferred stock, $25 par value. Authorized 2,000,000 shares; none issued and outstanding | $0 | $0 | ||
| Common stock, $.0667 par value. Authorized 120,000,000 shares; 32,058,121 shares issued and outstanding at December 31, 2025 and 32,527,244 shares issued and outstanding at December 31, 2024, respectively | $2.1M | $2.2M | ||
| Additional paid-in capital | $92.3M | $174.0M | ||
| Retained earnings | $1.1B | $997.5M | ||
| Accumulated other comprehensive income (loss) | $41.5M | -$23.7M | ||
| Total stockholders equity | $1.3B | $1.1B | $1.1B | $938.3M |
| Total liabilities and stockholders equity | $1.7B | $1.6B | ||
| Accounts receivable, allowance for doubtful accounts | $862.0K | $909.0K | ||
| Preferred stock, par value (in dollars per share) | $25.00 | $25.00 | ||
| Preferred stock, shares authorized (in shares) | 2.0M shares | 2.0M shares | ||
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | ||
| Common stock, par value (in dollars per share) | $0.07 | $0.07 | ||
| Common stock, shares authorized (in shares) | 120.0M shares | 120.0M shares | ||
| Common stock, shares issued (in shares) | 32.1M shares | 32.5M shares | ||
| Common stock, shares outstanding (in shares) | 32.1M shares | 32.5M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net earnings | $154.8M | $128.5M | $108.5M |
| Depreciation and amortization | $45.7M | $48.0M | $54.9M |
| Stock compensation expense | $18.1M | $16.7M | $16.1M |
| Deferred income taxes | $6.3M | -$6.8M | -$10.8M |
| (Recovery of) provision for credit losses | -$97.0K | $299.0K | $37.0K |
| Unrealized gain on foreign currency transactions and deferred compensation | -$680.0K | -$100.0K | -$733.0K |
| Asset impairment charge and (gain) loss on disposal of assets | -$58.0K | $1.7M | $7.0M |
| Change in fair value of contingent consideration liability | $0 | -$91.0K | -$11.3M |
| Accounts receivable | -$20.9M | $5.6M | $7.0M |
| Inventories | $3.6M | -$22.8M | $10.5M |
| Prepaid expenses and other current assets | -$1.3M | $225.0K | -$3.5M |
| Accounts payable and accrued expenses | $11.3M | $9.1M | $3.6M |
| Income taxes | -$1.1M | -$583.0K | $2.2M |
| Other | $865.0K | $2.4M | $305.0K |
| Net cash provided by operating activities | $216.6M | $182.0M | $183.8M |
| Capital expenditures and intangible assets acquired | -$43.5M | -$35.7M | -$37.9M |
| Cash paid for acquisitions, net of cash acquired | -$323.0K | -$24.2M | -$1.3M |
| Proceeds from sale of assets | $274.0K | $359.0K | $1.9M |
| Proceeds from settlement of net investment hedge | $0 | $0 | $2.7M |
| Investment in affiliates | -$353.0K | -$270.0K | -$290.0K |
| Net cash used in investing activities | -$43.9M | -$59.7M | -$34.8M |
| Proceeds from revolving loan | $88.0M | $26.0M | $18.0M |
| Principal payments on revolving debt | -$114.0M | -$145.6M | -$149.0M |
| Principal payments on finance lease | -$194.0K | -$216.0K | -$222.0K |
| Proceeds from stock options exercised | $9.3M | $17.2M | $5.2M |
| Dividends paid | -$28.3M | -$25.6M | -$22.9M |
| Repurchases of common stock | -$107.6M | -$5.7M | -$4.5M |
| Net cash used in financing activities | -$152.8M | -$133.8M | -$153.3M |
| Effect of exchange rate changes on cash | $5.2M | -$3.4M | $2.3M |
| Increase (decrease) in cash and cash equivalents | $25.1M | -$14.9M | -$2.1M |
No quarter-by-quarter statement was filed.
Corporate structure
BALCHEM CORP sits at the top of its group. 13 entities, 6 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of BALCHEM CORP
- VANGUARD CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G on BALCHEM CORP, latest Apr 29, 2026
- VANGUARD PORTFOLIO MANAGEMENT LLC Filed SCHEDULE 13G on BALCHEM CORP, latest Apr 28, 2026
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on BALCHEM CORP, latest Mar 26, 2026 (4 filings since Feb 9, 2022)
- BlackRock Filed SCHEDULE 13G/A on BALCHEM CORP, latest Jul 18, 2025 (6 filings since Jan 25, 2022)
- APG Asset Management US Inc. Filed SCHEDULE 13G/A on BALCHEM CORP, latest May 14, 2025 (5 filings since Feb 4, 2022)
- WASATCH ADVISORS LP Filed SC 13G/A on BALCHEM CORP, latest Nov 13, 2024 (4 filings since Feb 11, 2022)
- BALCHEM CORP Baltimore, Maryland, United States
- Aberco, Inc. Subsidiary · Maryland, United States
- Albion Laboratories, Inc. Subsidiary · Nevada, United States
- Balchem Canada Corporation Subsidiary · Canada
- Balchem Italia Srl Subsidiary · Italy
- Balchem Philippines, Inc. Subsidiary · Philippines
- BCP Ingredients, Inc. Subsidiary · Delaware, United States
- Kappa Bioscience AS Subsidiary · Norway
- Kappa Bioscience Europe GmbH Subsidiary · Germany
- Kappa Solutions AS Subsidiary · Norway
- Kechu BidCo AS Subsidiary · Norway
- SensoryEffects Cereal Systems, Inc. Subsidiary · Delaware, United States
- SensoryEffects, Inc. Subsidiary · Delaware, United States
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What BALCHEM CORP reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $564.4M6 Dec 31, 2025 | $511.2M6 Dec 31, 2024 | +10.4% |
| Accumulated depreciation | $257.7M6 Dec 31, 2025 | $229.0M6 Dec 31, 2024 | +12.5% |
| Property and equipment, net | $306.6M6 Dec 31, 2025 | $282.2M6 Dec 31, 2024 | +8.7% |
| Finance-lease assets | $1.5M6 Dec 31, 2025 | $1.7M6 Dec 31, 2024 | −12.1% |
| Operating-lease assets (leased space) | $14.7M6 Dec 31, 2025 | $15.3M6 Dec 31, 2024 | −4.2% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $74.6M6 Dec 31, 2025 | $49.5M6 Dec 31, 2024 | +50.6% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $816.4M6 Dec 31, 2025 | $780.0M6 Dec 31, 2024 | +4.7% |
| Indefinite-lived intangibles (excluding goodwill) | $06 Dec 31, 2025 | $06 Dec 31, 2024 | |
| Finite-lived intangibles, gross | $470.2M10 Dec 31, 2024 | $479.2M10 Dec 31, 2023 | −1.9% |
| Accumulated amortization | $305.2M10 Dec 31, 2024 | $288.0M10 Dec 31, 2023 | +6.0% |
| Finite-lived intangibles, net | $133.0M6 Dec 31, 2025 | $132.5M6 Dec 31, 2024 | +0.4% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $131.4M6 Dec 31, 2025 | $130.8M6 Dec 31, 2024 | +0.5% |
| Raw materials | $41.9M6 Dec 31, 2025 | $45.3M6 Dec 31, 2024 | −7.6% |
| Work in process | $6.5M6 Dec 31, 2025 | $4.5M6 Dec 31, 2024 | +44.7% |
| Finished goods | $83.1M6 Dec 31, 2025 | $81.0M6 Dec 31, 2024 | +2.6% |
Properties, in its own words
Our corporate headquarters is located in Montvale, New Jersey. Our operations are conducted at our owned and leased facilities throughout the U.S. and other foreign countries. These facilities house manufacturing and warehousing operations, as well as administrative offices. We have a total of 38 locations across the world and some of these manufacturing and warehousing locations serve multiple segments.
The following is a summary of our principal properties:
The rest of Item 2
Segment · Location · Administrative · Manufacturing · Warehousing
Corporate · 5 U.S. cities and 1 foreign country · 6 · — · —
HNH · 11 U.S. cities and 6 foreign countries · 1 · 16 · 7
ANH · 6 U.S. cities and 1 foreign country · — · 8 · 2
SP · 4 U.S. cities and 5 foreign countries · 1 · 7 · 2
Other · 2 U.S. cities and 1 foreign country · — · 3 · —
We believe that our production facilities and related machinery and equipment are well maintained, suitable for their purpose, and adequate to support our businesses.
Item 2 of the 10-K filed Feb 20, 2026.5
Leadership
Who has led BALCHEM CORP, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
- Chief executive officerTheodore L. Harris May 5, 2015 to now14
- Chief executive officerDino A. Rossi Oct 4, 2006 to Jun 12, 201515
- ChairTheodore L. Harris Sep 19, 2022 to now16
- ChairDino A. Rossi Jul 15, 2015 to Sep 17, 201517
- PresidentTheodore L. Harris May 5, 2015 to now14
- PresidentDino A. Rossi Oct 4, 2006 to Jun 12, 201515
- Chief financial officerCarl Martin Bengtsson Feb 5, 2019 to now18
- Chief financial officerTheodore L. Harris Feb 20, 2018 to Feb 16, 202119
- Chief financial officerMary Theresa Coelho Oct 25, 2017 to Oct 30, 201820
- Chief financial officerWilliam A. Backus Jun 20, 2014 to Mar 13, 201721
- Chief financial officerFrank Fitzpatrick Nov 17, 2006 to Jun 17, 201422
Board members and other officers (36)
- Chief Accounting OfficerErin Leigh Gilson Apr 7, 2026 to now23
- SVP and Chief R&D OfficerRen Anthony Gonzalez Sep 24, 2026 to now24
- SVP and Chief R&D OfficerGeorge Graham Oct 22, 2025 to now25
- EVP, Gen. Counsel & SecretaryHatsuki Miyata Feb 10, 2023 to Feb 14, 202526
- Vice PresidentGunsteren Job Leonard Van Feb 17, 2022 to now27
- Chief Supply Chain OfficerMartin Luther Reid Feb 17, 2022 to now28
- Chief Human Resources OfficerMichael Bent Tignor Feb 17, 2022 to now29
- Chief Technology OfficerMichael Robert Sestrick Feb 17, 2022 to Feb 14, 202530
- SVP/GM, Human Nutri. & HealthFrederic Boned Nov 3, 2022 to now31
- Sr. Vice PresidentJames C. Hyde Feb 16, 2021 to Feb 16, 202232
- Vice PresidentScott C. Mason Feb 19, 2019 to Nov 16, 202033
- Vice President - OperationsJohn Edward Kuehner Mar 2, 2017 to Mar 2, 201734
- Pres Perf Chemical and Ingr CoCharles A. Nicolais May 19, 2014 to May 19, 201435
- Vice PresidentFrank Fitzpatrick Jun 17, 2014 to Feb 23, 201736
- Chief Accounting OfficerWilliam A. Backus Sep 26, 2011 to now37
- VP, Human ResourcesRobert T. Miniger Mar 24, 2006 to May 14, 200838
- VP Research and DevelopmentPaul H. Richardson Nov 22, 2006 to May 10, 201139
- VP/Gen Mgr/ARC Spec ProdsDavid F. Ludwig Dec 12, 2006 to Nov 13, 201940
- Board memberMonica Vicente Sep 8, 2023 to now41
- Board memberOlivier Rigaud Sep 8, 2023 to now42
- Board memberKathleen B. Fish Jun 21, 2021 to now43
- Board memberJoyce J. Lee Sep 12, 2019 to Feb 12, 202444
- Board memberDaniel E. Knutson Feb 6, 2018 to now45
- Board memberTheodore L. Harris May 5, 2015 to Feb 16, 202214
- Board memberMatthew David Wineinger Sep 24, 2015 to now46
- Board memberPaul D. Coombs Sep 24, 2010 to Feb 16, 202147
- Board memberPerry W. Premdas Jan 3, 2008 to Feb 10, 202348
- Board memberEdward McMillan Jan 3, 2006 to Jun 21, 201849
- Board memberElaine R. Wedral Jan 3, 2006 to Dec 24, 201350
- Board memberHoyt Ammidon Jr. Jan 3, 2006 to Mar 21, 200851
- Board memberJohn Y. Televantos Jan 3, 2006 to Feb 15, 202352
- Board memberKenneth P. Mitchell Jan 3, 2006 to Feb 23, 201053
- Board memberDino A. Rossi Dec 12, 2006 to Dec 8, 201654
- General counselHatsuki Miyata Aug 1, 2022 to now55
- General counselMark A. Stach Feb 21, 2018 to Feb 16, 202256
- General counselMatthew David Houston Mar 1, 2006 to Sep 21, 201657
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- Aberco, Inc. Maryland4
- Albion Laboratories, Inc. Nevada4
- BCP Ingredients, Inc. Delaware4
- Balchem BV Netherlands4
- Balchem Canada Corporation Canada4
- Balchem Italia Srl Italy4
- Balchem Ltd. Canada4
- Balchem NV Belgium4
- Balchem Philippines, Inc. Philippines4
- Balchem Pty Ltd. Australia4
- Balchem Sdn Bhd Malaysia4
- Kappa Bioscience AS Norway4
- Kappa Bioscience Europe GmbH Germany4
- Kappa Solutions AS Norway4
- Kechu BidCo AS Norway4
- SensoryEffects Cereal Systems, Inc. Delaware4
- SensoryEffects, Inc. Delaware4
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Timeline
- Jul 31, 20268-K Results of operations58
- Jul 27, 20268-K Entered a material agreement; New debt or obligation59
- Jun 22, 20268-K Shareholder vote60
- Apr 30, 20268-K Results of operations61
- Feb 20, 20268-K Results of operations62
- Feb 19, 20268-K Executive or director change63
- Dec 10, 20258-K Regulation FD disclosure64
- Oct 21, 20258-K Results of operations65
- Jul 31, 20258-K Results of operations66
- Jun 20, 20258-K Shareholder vote67
- Apr 24, 20258-K Results of operations68
- Mar 3, 20258-K Executive or director change69
- May 5, 2015New chief executive Theodore L. Harris becomes CEO14
- Oct 4, 2006New chief executive Dino A. Rossi becomes CEO15
- Jan 29, 1967Founded BALCHEM CORP is founded2
Calendar
Coming up
- Oct 23, 2026 · Before the openReports results for the quarter ending Sep/2026 A year earlier it reported $1.35 a share, on Oct 21, 2025.70
When it reported results
- Jul 31, 2026Reported quarterly or annual results58
- Apr 30, 2026Reported quarterly or annual results61
- Feb 20, 2026Reported quarterly or annual results62
- Oct 21, 2025Reported quarterly or annual results65
- Jul 31, 2025Reported quarterly or annual results66
- Apr 24, 2025Reported quarterly or annual results68
- Feb 21, 2025Reported quarterly or annual results71
- Oct 25, 2024Reported quarterly or annual results72
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
305 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 46 major events, 176 insider forms, 21 large holders, 42 other. The latest 20:
- Sep 24, 20263 EDGAR
- Jul 31, 202610-Q EDGAR
- Jul 31, 20268-K EDGAR
- Jul 27, 20268-K EDGAR
- Jun 22, 20268-K EDGAR
- Jun 18, 202611-K EDGAR
- Apr 30, 202610-Q EDGAR
- Apr 30, 20268-K EDGAR
- Apr 29, 2026SCHEDULE 13G EDGAR
- Apr 28, 2026SCHEDULE 13G EDGAR
- Apr 27, 2026DEFA14A EDGAR
- Apr 27, 2026DEF 14A EDGAR
- Apr 7, 20263 EDGAR
- Mar 26, 2026SCHEDULE 13G/A EDGAR
- Feb 20, 202610-K EDGAR
- Feb 20, 20268-K EDGAR
- Feb 19, 20268-K EDGAR
- Feb 13, 20264 EDGAR
- Feb 13, 20264 EDGAR
- Feb 13, 20264 EDGAR
The 305 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
22 open-market trades by officers, directors and large owners since October 2021: 0 buys and 22 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Dec 4, 2025 | van Gunsteren Job LeonardSVP and GM, Specialty Products | Sale | 6,000 | $153.28 | $919.7K | Form 4 |
| Dec 3, 2025 | Fischer David BDirector | Sale | 8,000 | $153.97 | $1.2M | Form 4 |
| Nov 11, 2025 | Reid Martin LutherSVP Chief Supply Chain Officer | Sale | 1,200 | $154.44 | $185.3K | Form 4 |
| Jul 31, 2024 | van Gunsteren Job LeonardSVP and GM, Specialty Products | Sale | 7,750 | $180.05 | $1.4M | Form 4 |
| Jul 30, 2024 | Backus William A.VP & Chief Accounting Officer | Sale | 4,804 | $178.93 | $859.6K | Form 4 |
| May 10, 2024 | Sestrick Michael RobertSVP & Chief Technology Officer | Sale | 1,929 | $154.45 | $297.9K | Form 4 |
| May 8, 2024 | Fischer David BDirector | Sale | 5,000 | $152.98 | $764.9K | Form 4 |
| Mar 8, 2024 | Tignor Michael BrentSVP & Chief HR Officer | Sale | 5,339 | $157.52 | $841.0K | Form 4 |
| Mar 4, 2024 | Wineinger Matthew DavidDirector | Sale | 1,333 | $156.89 | $209.1K | Form 4 |
| Feb 26, 2024 | Backus William A.VP & Chief Accounting Officer | Sale | 7,000 | $155.19 | $1.1M | Form 4 |
| Feb 23, 2024 | Backus William A.VP & Chief Accounting Officer | Sale | 9,180 | $156.37 | $1.4M | Form 4 |
| Feb 22, 2024 | Harris Theodore LChairman, President & CEO | Sale | 34,350 | $154.30 | $5.3M | Form 4 |
| Feb 21, 2024 | Backus William A.VP & Chief Accounting Officer | Sale | 15,000 | $154.73 | $2.3M | Form 4 |
| Feb 21, 2024 | Sestrick Michael RobertSVP & Chief Technology Officer | Sale | 11,100 | $153.21 | $1.7M | Form 4 |
| Feb 21, 2024 | Harris Theodore LChairman, President & CEO | Sale | 29,679 | $153.58 | $4.6M | Form 4 |
| Sep 11, 2023 | Fischer David BDirector | Sale | 3,800 | $131.57 | $500.0K | Form 4 |
| May 2, 2023 | Sestrick Michael RobertSVP & Chief Technology Officer | Sale | 2,300 | $130.36 | $299.8K | Form 4 |
| Mar 20, 2023 | Fischer David BDirector | Sale | 3,000 | $127.01 | $381.0K | Form 4 |
| Aug 12, 2022 | van Gunsteren Job LeonardSVP and GM, Specialty Products | Sale | 1,000 | $131.12 | $131.1K | Form 4 |
| Aug 5, 2022 | van Gunsteren Job LeonardSVP and GM, Specialty Products | Sale | 2,629 | $127.01 | $333.9K | Form 4 |
All 22 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- VANGUARD CAPITAL MANAGEMENT LLCSCHEDULE 13G, 1 filing Apr 29, 202673
- VANGUARD PORTFOLIO MANAGEMENT LLCSCHEDULE 13G, 1 filing Apr 28, 202674
- VANGUARD GROUP INCSCHEDULE 13G/A, 4 filings Feb 9, 2022 to Mar 26, 202675
- BlackRockSCHEDULE 13G/A, 6 filings Jan 25, 2022 to Jul 18, 202576
- APG Asset Management US Inc.SCHEDULE 13G/A, 5 filings Feb 4, 2022 to May 14, 202577
- WASATCH ADVISORS LPSC 13G/A, 4 filings Feb 11, 2022 to Nov 13, 202478
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Ted HarrisChairman, President and Chief Executive Officer | $1.2M | $7.9M79 | |
| 2025 | C. Martin BengtssonExecutive Vice President and Chief Financial Officer | $614.4K | $3.0M79 | |
| 2025 | Hatsuki MiyataExecutive Vice President, Chief Legal Officer and Secretary | $526.2K | $2.4M79 | |
| 2025 | Frederic BonedSenior Vice President and General Manager, Human Nutrition and Health | $542.3K | $2.3M79 | |
| 2025 | M. Brent TignorSenior Vice President and Chief Human Resources Officer 6 | $446.7K | $1.8M79 | |
| 2024 | Ted HarrisChairman, President and Chief Executive Officer | $1.2M | $6.9M79 | |
| 2024 | C. Martin BengtssonExecutive Vice President and Chief Financial Officer | $572.1K | $2.4M79 | |
| 2024 | Frederic BonedSenior Vice President and General Manager, Human Nutrition and Health | $518.1K | $1.9M79 | |
| 2024 | Hatsuki MiyataExecutive Vice President, Chief Legal Officer and Secretary | $471.1K | $1.6M79 | |
| 2023 | Ted HarrisChairman, President and Chief Executive Officer | $1.2M | $5.9M79 | |
| 2023 | C. Martin BengtssonExecutive Vice President and Chief Financial Officer | $527.3K | $1.8M79 | |
| 2023 | Frederic BonedSenior Vice President and General Manager, Human Nutrition and Health | $432.8K | $1.1M79 | |
| 2023 | Hatsuki MiyataExecutive Vice President, Chief Legal Officer and Secretary | $435.9K | $1.1M79 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 4,964,479 | $838.7M | 0.0% | +122,882 |
| Vanguard Portfolio Management LLC | 2,221,267 | $375.3M | 0.0% | +27,850 |
| Vanguard Capital Management LLC | 1,445,369 | $244.2M | 0.0% | +13,281 |
| State Street Corp | 1,281,552 | $216.5M | 0.0% | +40,816 |
| Geode Capital Management, LLC | 1,122,146 | $189.6M | 0.0% | +74,947 |
| Conestoga Capital Advisors, LLC | 1,087,871 | $183.8M | 4.0% | −163,318 |
| Wasatch Advisors LP | 1,050,780 | $177.5M | 1.2% | −372,644 |
| Morgan Stanley | 834,445 | $141.0M | 0.0% | −22,924 |
| Geneva Capital Management LLC | 683,102 | $115.4M | 2.6% | −163,393 |
| First Trust Advisors LP | 617,233 | $104.3M | 0.1% | +163,896 |
| Dimensional Fund Advisors LP | 610,047 | $103.1M | 0.0% | +13,319 |
| Fmr LLC | 560,255 | $94.7M | 0.0% | −38,415 |
| Congress Asset Management Co | 502,571 | $84.9M | 0.5% | +56,758 |
| Two Sigma Investments, LP | 502,038 | $84.8M | 0.1% | +71,828 |
| Schroder Investment Management Group | 440,418 | $74.5M | 0.1% | +79,922 |
| Nuveen, LLC | 414,367 | $70.0M | 0.0% | +20,882 |
| Norges Bank | 411,876 | $69.6M | 0.0% | New |
| Northern Trust Corp | 384,172 | $64.9M | 0.0% | +10,188 |
| Charles Schwab Investment Management Inc | 374,613 | $63.3M | 0.0% | +5,150 |
| Jpmorgan Chase & Co | 341,653 | $58.1M | 0.0% | −85,346 |
| William Blair Investment Management, LLC | 314,063 | $53.1M | 0.2% | −1,197 |
| Goldman Sachs Group Inc | 272,008 | $46.0M | 0.0% | +103,636 |
| Stephens Investment Management Group LLC | 270,501 | $45.7M | 0.5% | +4,415 |
| Clearbridge Investments, LLC | 243,769 | $41.2M | 0.0% | −13,044 |
| Vanguard Fiduciary Trust Co | 229,743 | $38.8M | 0.0% | +3,643 |
13F reports cover disclosed long positions in U.S. stocks only.
Members of Congress who traded it
4 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.
| Date | Member | Trade | Amount | Vs S&P since | Filing |
|---|---|---|---|---|---|
| Sep 17, 2026 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | +1.8% | Report |
| Jul 10, 2026 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | +3.1% | Report |
| Apr 9, 2025 | Josh GottheimerDemocratic, House | Partial sale | $1,001 - $15,000 | +33.7% | Report |
| Jun 24, 2019 | Donna Shalala, House | Sale | $1,001 - $15,000 | +87.5% | Report |
Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).
SEC filer profile
How BALCHEM CORP is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARBALCHEM CORP1
- CIK0000009326
- Employer ID (EIN)13-25784325
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company5
- Incorporated inMaryland5
- Fiscal year endsDecember 311
- Industry code (SIC)2800 Chemicals & Allied Products1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address5 Paragon Drive, Montvale, NJ 076451
- Phone(845) 326-56001
- Shares outstanding31,878,021 as of Jul 23, 202612
- Public float$5.1B as of Jun 30, 20255
- AuditorRSM US LLP, New York, New York PCAOB ID 49; it also attests to the company’s internal control over financial reporting5
- On EDGAR sinceAug 11, 19951
- Filings1,273 in all: 4 (611), 8-K (207), 10-Q (86), SC 13G/A (86), 3 (35), 4/A (30), DEF 14A (30), 10-K (28)1
All 35 form types
11-K (28), 144 (22), SC 13G (17), DEFA14A (11), UPLOAD (11), 10QSB (8), ARS (8), CORRESP (8), 8-K/A (7), S-8 (7), IRANNOTICE (5), 10QSB/A (4), SCHEDULE 13G/A (4), 10KSB (3), PRE 14A (3), 144/A (2), SCHEDULE 13G (2), 10-K/A (1), 10-Q/A (1), 10KSB/A (1), 11-K/A (1), 25 (1), 3/A (1), 8-A12B (1), CERTNAS (1), DEFR14A (1), S-8 POS (1)
- Latest filingsAnnual report (10-K) Feb 20, 2026
Quarterly report (10-Q) Jul 31, 2026
Proxy statement (DEF 14A) Apr 27, 2026
Latest 8-K (8-K) Jul 31, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, par value $.06-2/3 per share | BCPC | The Nasdaq Stock Market LLC |
From the cover page of the 10-K filed Feb 20, 2026 (Section 12(b) of the Exchange Act).5
Risk factors and legal proceedings
The risks BALCHEM CORP names in Item 1A of its 10-K filed Feb 20, 2026: 26 risks under these headings, as written.5
- Operational Risks
- We face risks associated with our sales to customers and manufacturing operations outside the United States.
- Our sales and operations may be adversely affected by supply chain disruptions due to political unrest, terrorist acts, and national and international conflicts.
- Our financial success depends in part on the reliability and sufficiency of our manufacturing facilities.
- Our ability to successfully grow and expand our business depends on our ability to recruit and retain a highly qualified and motivated workforce.
- We may, from time to time, experience problems in our labor relations.
- The effects of global climate change or other unexpected events, including global health crises, may disrupt our operations and have a negative impact on our business.
- We may be subject to risks relating to our information technology and operational technology systems.
- We currently rely on third-party service providers for many of the critical elements of our global information and operational technology infrastructure and their failure to provide effective support for such infrastructure could negatively impact our business and financial results.
- Disruptions or breaches of our information systems could adversely affect us.
- Business and Financial Risks
- Increased competition could adversely affect our business and financial results.
The other 16 risks
- Global economic conditions may adversely affect our business, operating results and financial condition.
- Raw material shortages or price increases could adversely affect our business and financial results.
- Our international operations subject us to currency translation risk and currency transaction risk which could cause our results to fluctuate from period to period.
- Our debt instruments are subject to interest rate risks and impose operating and financial restrictions which could have an adverse impact on our business and results of operations.
- We may not be able to successfully consummate and manage acquisition, joint venture and divestiture activities which could have an impact on our results.
- We may not be able to effectively manage and implement restructuring initiatives or other organizational changes.
- Changes in our relationships with our vendors, changes in tax or trade policy, interruptions in our operations or supply chain or increased commodity or supply chain costs could adversely affect our results of operations.
- Adverse publicity or consumer concern regarding the safety or quality of food products containing our products, or health concerns, whether with our products, products in the same general class as our products or for food products containing our products, may result in the loss of sales. Also, consumer preferences for products containing our products may change.
- Legal, Regulatory and Compliance Risks
- Material adverse legal judgments, fines, penalties or settlements could adversely affect our business.
- Our business exposes us to potential product liability claims and recalls, which could adversely impact our financial condition and performance.
- Our brands are important assets of our businesses, and violation of our trademark rights by imitators could negatively impact revenues and brand reputation.
- Allegations that we have infringed the intellectual property rights of third parties could negatively affect us.
- We are subject to risks related to sustainability and corporate social responsibility and various reputational matters.
- Our reputation, ability to do business and results of operations could be impaired by adverse publicity or improper conduct by any of our employees, agents or business partners.
- Our operations are subject to regulatory risks and the loss of governmental permits and approvals would materially and adversely affect some of our businesses.
- Concerns about ethylene oxide emissions have resulted in regulatory requirements for ethylene oxide users that have impacted, and may continue to impact, such users' ability to use the ethylene oxide process to sterilize medical devices among other things, which may, in turn, affect sales to our customers and our operations.
Legal proceedings
In the normal course of business, we are involved in a variety of lawsuits, claims and legal proceedings, from time to time, including commercial and contract disputes, labor and employment matters, product liability claims, environmental liabilities, trade regulation matters, intellectual property disputes and tax-related matters. Further, in connection with normal operations at our plant facilities, our manufacturing sites may, from time to time, be subject to inspections or inquiries by the EPA and other agencies. To the extent any consent orders or other agreements are entered into as a result of findings from such inspections or inquiries, the Company is committed to ensuring compliance with such orders or agreements.
Information with respect to certain legal proceedings is included in Note 15, Commitments and Contingencies, to our Consolidated Financial Statements for the year ended December 31, 2025 contained in this Annual Report on Form 10-K, and is incorporated herein by reference.
In our opinion, we do not expect pending legal matters to have a material adverse effect on our consolidated financial position, results of operations, liquidity or cash flows.
The opening of Item 3, Legal Proceedings.5
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARBALCHEM CORP filings on SEC EDGAR
- 2
- 3SEC EDGARBALCHEM CORP filings on SEC EDGAR
- 4
- 5
- 6SEC EDGARBALCHEM CORP 10-K for fiscal 2025
- 7SEC EDGARBALCHEM CORP 10-K for fiscal 2019
- 8SEC EDGARBALCHEM CORP 10-K for fiscal 2020
- 9SEC EDGARBALCHEM CORP 10-K for fiscal 2021
- 10SEC EDGARBALCHEM CORP 10-K for fiscal 2022
- 11SEC EDGARBALCHEM CORP 10-Q for fiscal 2026
- 12SEC EDGARBALCHEM CORP 10-Q for fiscal 2026
- 13SEC EDGARBALCHEM CORP 10-K for fiscal 2019
- 14
- 15
- 16SEC EDGARTheodore L. Harris, Chair
- 17SEC EDGARDino A. Rossi, Chair
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32SEC EDGARJames C. Hyde, Sr. Vice President
- 33SEC EDGARScott C. Mason, Vice President
- 34
- 35
- 36SEC EDGARFrank Fitzpatrick, Vice President
- 37
- 38
- 39
- 40
- 41SEC EDGARMonica Vicente, Board member
- 42SEC EDGAROlivier Rigaud, Board member
- 43SEC EDGARKathleen B. Fish, Board member
- 44SEC EDGARJoyce J. Lee, Board member
- 45SEC EDGARDaniel E. Knutson, Board member
- 46
- 47SEC EDGARPaul D. Coombs, Board member
- 48SEC EDGARPerry W. Premdas, Board member
- 49SEC EDGAREdward McMillan, Board member
- 50SEC EDGARElaine R. Wedral, Board member
- 51SEC EDGARHoyt Ammidon Jr., Board member
- 52SEC EDGARJohn Y. Televantos, Board member
- 53SEC EDGARKenneth P. Mitchell, Board member
- 54SEC EDGARDino A. Rossi, Board member
- 55SEC EDGARHatsuki Miyata, General counsel
- 56SEC EDGARMark A. Stach, General counsel
- 57
- 58SEC EDGARResults of operations
- 59
- 60SEC EDGARShareholder vote
- 61SEC EDGARResults of operations
- 62SEC EDGARResults of operations
- 63SEC EDGARExecutive or director change
- 64SEC EDGARRegulation FD disclosure
- 65SEC EDGARResults of operations
- 66SEC EDGARResults of operations
- 67SEC EDGARShareholder vote
- 68SEC EDGARResults of operations
- 69SEC EDGARExecutive or director change
- 70NasdaqNasdaq calendar
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79